Moleculin Biotech Inc. Highlights Progress of Annamycin in Acute Myeloid Leukemia (AML) Program

Moleculin Biotech Inc. (Nasdaq: MBRX) announced on October 30, 2025 that it will present its ongoing Phase 3 Acute Myeloid Leukemia (AML) “MIRACLE” clinical trial at the 14th Annual Acute Leukemia Meeting. The meeting will take place October 30‑31, 2025 at the MD Anderson Cancer Center Spain Foundation in Madrid, Spain.

Presentation Details

  • Title: L‑Annamycin – Non‑Cardiotoxic Anthracycline; MIRACLE Pivotal AML Study
  • Session: Lunch session
  • Presenter: Dr. Paul Waymack, Senior Chief Medical Officer of Moleculin
  • Date and Time: Thursday, October 30 at 2:35 PM CEST

Dr. Waymack will discuss the company’s Phase 2B/3, multi‑center, randomized, double‑blind, placebo‑controlled, adaptive‑design study of Annamycin in combination with cytarabine (Ara‑C). The study is a pivotal program for the MIRACLE trial, which is designed to evaluate the efficacy and safety of Annamycin plus Ara‑C in patients with newly diagnosed AML.

Recent Developments in the Annamycin Portfolio

  • October 29, 2025 – Moleculin announced the addition of a new Australian patent covering Annamycin, expanding the company’s global intellectual‑property portfolio.
  • October 30, 2025 – The company will also present at a conference in Madrid, Spain, where it will share interim results of the Annamycin AML study. The presentation is scheduled for the lunch session of the meeting and will be led by Dr. Waymack.

Company Context

Moleculin Biotech is a preclinical and clinical‑stage pharmaceutical company headquartered in Houston, Texas. The company focuses on developing anti‑cancer drug candidates and operates within the biotechnology sector of the health care industry. Its product pipeline includes drugs for skin diseases and cancer care. Moleculin went public on June 2, 2016, and its shares trade on the Nasdaq exchange.

Market Information (as of 2025‑10‑29)

  • Closing price: $0.452
  • 52‑week high: $3.65 (February 12, 2025)
  • 52‑week low: $0.25 (June 19, 2025)
  • Market capitalization: $25,150,000
  • Price‑earnings ratio: –0.15

The upcoming presentation at the Acute Leukemia Meeting is expected to provide further insight into the progress of Moleculin’s Annamycin program and its potential impact on the company’s clinical and commercial prospects.